Çѱ¹¹ÙÀÌ¿ÀÀǾàÇ°Çùȸ ´º½º·¹ÅÍ ±¹¹® Å×½ºÆ®ÆÄÀÏ
|
|
|
|
|
ÀÇ°ßÁ¶È¸
|
¡ºÁ¤¸ÆÁÖ»ç¿ë Á¤»ó »ç¶÷ ¸é¿ª±Û·ÎºÒ¸°ÀÇ ¾ÈÀü¼º¡¤À¯È¿¼º Æò°¡ °¡À̵å¶óÀΡ» Á¦Á¤(¾È) ÀÇ°ßÁ¶È¸(~10/19±îÁö)
<¸ñÀû>
IVIG¿¡ ´ëÇÑ ÀÓ»ó½ÃÇèÀÇ °èȹ ¹× Æò°¡¹æ¹ý µî ÀÓ»ó½ÃÇè ½Ç½Ã¿¡ ÇÊ¿äÇÑ ±Ç°í»çÇ×À» ÀÓ»ó½ÃÇè ¼öÇàÀÚ¿¡°Ô Á¦°øÇÔ°ú µ¿½Ã¿¡ ÀÓ»ó½ÃÇè °èȹ¼ÀÇ ½É»ç¿¡ È°¿ëÇÏ¿© ÀÓ»ó½ÃÇèÀÇ Ç¥ÁØÈ⋅±¹Á¦ÈÇÔÀ¸·Î½á, Á¦Ç°¿¡ ´ëÇÑ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» È®º¸ÇÏ´Â µ¥ ±× ¸ñÀûÀÌ ÀÖ´Ù.
<ÁÖ¿ä ³»¿ë>
1. ÀϹÝÀû °í·Á»çÇ× (À¯È¿¼º, ¾ÈÀü¼º)
2. Ç°¸ñÇã°¡ ½Åû ½Ã °í·Á»çÇ×
3. Ç°¸ñÇã°¡ ÈÄ Á¦Á¶¹æ¹ý º¯°æ ½Ã °í·Á»çÇ×
<ÀÇ°ß Á¦Ãâ>
±âÇÑ : 2017. 10. 19. (¸ñ)
Á¦Ãâó : info@kobia.kr
Á¦Á¤¾È È®ÀÎ |
|
|
ÀÔ¹ý¿¹°í |
ÀǾàÇ° µîÀÇ ¾ÈÀü¿¡ °üÇÑ ±ÔÄ¢ ÀϺΰ³Á¤·É(¾È) ÀÔ¹ý¿¹°í ¾Ë¸²
<°³Á¤ÀÌÀ¯>
ÀǾàÇ° Á¦Á¶¾÷ÀÚ µîÀÌ Á¦Á¶¾÷Çã°¡¸¦ µæÇÏ¿© Ç°¸ñÇã°¡(½Å°í) µîÀ» ¹ÞÀº ÀǾàÇ°À» µ¿¹°¿ëÀ¸·Î »ç¿ëÇϱâ À§ÇÑ ¸ñÀûÀ¸·Î ÆǸÅÇϱâ À§ÇØ °ü·Ã Áß¾ÓÇàÁ¤±â°üÀÇ Àå¿¡°Ô ÇÊ¿äÇÑ Çã°¡ ½É»ç µîÀ» ½ÅûÇÑ °æ¿ì, Á¦Á¶¾÷ Çã°¡¿Í Á¦Á¶ ¹× Ç°Áú°ü¸®±âÁØ Æò°¡ µîÀ» ¸éÁ¦Çϱâ À§ÇÏ¿© ÀÌ¹Ì ¹ß±ÞµÇ¾î ÀÖ´Â Á¦Á¶¾÷ Çã°¡Áõ, Á¦Á¶ ¹× Ç°Áú°ü¸®±âÁØ ÀûÇÕÆÇÁ¤¼ µîÀ» ÇØ´ç Áß¾ÓÇàÁ¤±â°üÀÇ Àå¿¡°Ô Á¦°øÇÒ ¼ö ÀÖ´Â ±Ù°Å¸¦ ¸¶·ÃÇÏ´Â ÇÑÆí,
ÀÓ»ó½ÃÇè Áß »ç¸ÁÀ» ÃÊ·¡Çϰųª »ý¸íÀ» À§ÇùÇÏ´Â ¾à¹°ÀÌ»ó¹ÝÀÀ ¹ß»ý ½Ã º¸°í±âÇÑ¿¡ ´ëÇÑ È¥¼± ¹ß»ýÀ» ¹æÁöÇϱâ À§ÇÏ¿© ±ÔÁ¤À» ¸íÈ®ÇÏ°Ô ÇÏ´Â µî ±× ¹Û¿¡ ÇöÇà Á¦µµÀÇ ¿î¿µ»ó ³ªÅ¸³ ÀϺΠ¹ÌºñÁ¡À» °³¼±․º¸¿ÏÇÏ°íÀÚ ÇÔ
<ÁÖ¿ä³»¿ë>
1. ȯÀÚ Ä¡·á±âȸ È®´ë¸¦ À§ÇÑ ÀÓ»ó½ÃÇè Á¤º¸ µî·ÏÁ¦µµ µµÀÔ(¾È Á¦30Á¶ ¹× Á¦31Á¶)
±âÁ¸ÀÇ Ä¡·áÁ¦¿¡ ºñÇØ È¹±âÀû È¿°ú¸¦ °¡Áø ½Å¾à °³¹ßÀ» À§ÇÑ ÀÓ»ó½ÃÇè¿¡ Âü¿©ÇÏ´Â °ÍÀº ÁßÁõÁúȯÀ» ¾Î°í Àִ ȯÀÚµé°ú ±× °¡Á·µé¿¡°Ô´Â ¸¶Áö¸· Ä¡·á±âȸ°¡ µÉ ¼ö ÀÖÀ½¿¡µµ, ÀÓ»ó½ÃÇè°èȹ ½ÂÀο¡ °üÇÑ Á¤º¸ÀÇ °ø°³°¡ Á¦ÇÑÀûÀ¸·Î ÀÌ·ç¾îÁö°í ÀÖ¾î ÀÌ¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Á¦°íÇÏ°í ÀÓ»ó½ÃÇè Á¤º¸ °ü¸®ÀÇ È¿À²¼º ¹× Á¤È®¼ºÀ» µµ¸ðÇÏ°íÀÚ ÀÓ»ó½ÃÇè Á¤º¸ µî·Ï ¹× °ø°³ Á¦µµ¿¡ °üÇÑ ±Ù°Å¸¦ ¸¶·ÃÇÔ |
2. À§ÇØ(êËúª)ÀǾàÇ°µî ȸ¼ö°á°ú °ø°³ ±Ù°Å ¸¶·Ã(¾È Á¦90Á¶)
3. ÀǾàÇ° Á¦Á¶ ¹× Ç°Áú°ü¸®±âÁØ ÀûÇÕÆÇÁ¤¼ Àç¹ß±Þ ÀýÂ÷ ¸¶·Ã(¾È Á¦96Á¶ µî)
ÀǾàÇ°½Ç»ç»óÈ£Çù·Â±â±¸(PIC/S) °¡ÀÔ(`14.7.) ¹× ±¹Á¦Á¶È¸¦ À§ÇØ ÀǾàÇ° Á¦Á¶ ¹× Ç°Áú°ü¸®(GMP) ÀûÇÕÆÇÁ¤¼ ¹ß±ÞÁ¦µµ°¡ µµÀÔ(`14.10.10. °³Á¤, `14.12.19. ½ÃÇà)µÇ¾úÀ¸³ª, ÆÇÁ¤¼ ¹ß±Þ ÈÄ Àç¹ß±Þ, ÁöÀ§½Â°è¸¦ À§ÇÑ ¹ýÀû±Ù°Å°¡ ¾ø¾î ÀǾàÇ°µî Á¦Á¶¾÷ÀÚ°¡ GMP ÀûÇÕÆÇÁ¤¼¸¦ ¹ß±Þ¹ÞÀº ÈÄ ºÐ½Ç, ¼Õ»óµÇ°Å³ª, Á¦Á¶¾÷ÀÇ ¾çµµ¡¤¾ç¼ö, »ó¼Ó µî¿¡ µû¶ó ÀûÇÕÆÇÁ¤¼ÀÇ Àç¹ß±Þ ¶Ç´Â ÁöÀ§¸¦ ½Â°èÇÏ°íÀÚ ÇÏ´Â °æ¿ì ½Å±Ô GMP ½Åû¼ Á¦Ãâ¿¡ µû¸¥ ºÎ´ãÀÌ ¼ö¹ÝµÇ´Â¹Ù, ÀÌ·¯ÇÑ ºÒÆíÀ» ÇؼÒÇϱâ À§ÇØ GMP ÀûÇÕÆÇÁ¤¼ÀÇ Àç¹ß±Þ ¹× ÁöÀ§½Â°è¸¦ À§ÇÑ ¹ýÀû ±Ù°Å¸¦ ¸¶·ÃÇÔ
|
4. ÀÓ»ó½ÃÇè ¾à¹°ÀÌ»ó¹ÝÀÀ º¸°í±âÇÑ ¸íÈ®È(¾È º°Ç¥ 4) µî
<ÀÇ°ß Á¦Ãâ>
±âÇÑ : 2017. 10. 26. (¸ñ)
Á¦Ãâó : info@kobia.kr
ÀϺΰ³Á¤·É(¾È) È®ÀÎ |
|
|
|
|
|
|
|
½ÅûÀÚ |
½ÂÀÎÀÏ |
Á¦Ç°¸í |
ÀÓ»ó |
´Ü°è |
»ï¼º¹ÙÀÌ¿À¿¡Çǽº ÁÖ½Äȸ»ç |
20170918 |
½Å»ýÇ÷°ü¼º ¿¬·É °ü·Ã Ȳ¹Ýº¯¼ºÀÌ ÀÖ´Â ½ÃÇè´ë»óÀÚ¿¡¼ SB11(¶ó´ÏºñÁÖ¸¿ µ¿µî»ý¹°ÀǾàÇ°)°ú ·ç¼¾Æ¼½º? °£ À¯È¿¼º, ¾ÈÀü¼º, ¾àµ¿ÇÐ ¹× ¸é¿ª¿ø¼ºÀ» ºñ±³ÇÏ´Â Á¦ 3»ó, ¹«ÀÛÀ§ ¹èÁ¤, ÀÌÁß ´«°¡¸², ÆòÇ౺, ´Ù±â°ü ÀÓ»ó½ÃÇè |
3»ó |
SB11ÁÖ 10
(
¹Ð¸®±×¶÷/¹Ð¸®¸®ÅÍ)
SB11 |
Áø¿ø»ý¸í°úÇÐ(ÁÖ) |
20170914 |
CELLECTRA? 2000 (Electroporation, EP)¸¦ »ç¿ëÇÏ¿© Çdz»(Intradermal, ID)¿¡ Á¢Á¾ÇÏ´Â GLS-5300ÀÇ ¾ÈÀü¼º, ³»¾à¼º ¹× ¸é¿ª¿ø¼ºÀ» Ž»öÇϱâ À§ÇÑ °ø°³, ¿ë·® Áõ·®, Á¦ I/IIa ÀÓ»ó½ÃÇè |
1»ó |
GLS-5300 |
Çѱ¹¾Öºêºñ(ÁÖ) |
20170914 |
Àû¾îµµ 1°¡Áö ÀÌ»óÀÇ ºñ»ý¹°ÇÐÀû Áúº´Á¶ÀýÇ×·ù¸¶Æ¼½ºÁ¦(DMARD)¿¡ ºÒÃæºÐÇÑ ¹ÝÀÀÀ» º¸ÀÎ ÀÌ·ÂÀÌ ÀÖ´Â È°µ¿¼º °Ç¼±¼º °üÀý¿° ȯÀÚ¸¦ ´ë»óÀ¸·Î ABT-494¸¦ À§¾à ¹× Adalimumab°ú ºñ±³ Æò°¡ÇÏ´Â Á¦3»ó, ¹«ÀÛÀ§¹èÁ¤, ÀÌÁß´«°¡¸² ÀÓ»ó½ÃÇè - SELECT - PsA 1
|
1»ó |
ABT494 |
Çѱ¹ÈÀÌÀÚÁ¦¾à(ÁÖ) |
20170914 |
´ÙºÐÀý ±â±â °íÁ¤¼ú°ú ÇÔ²² ¼±ÅÃÀû °³¹æ ôÃß ÈĹæ À¯ÇÕ¼úÀ» ¹Þ´Â ¼ºÀο¡¼ Ȳ»öÆ÷µµ»ó±¸±Õ 4-Ç׿ø ¹é½Å(SA4Ag)ÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» Æò°¡Çϱâ À§ÇÑ Á¦ 2b »ó, ¹«ÀÛÀ§¹èÁ¤, ÀÌÁß´«°¡¸², À§¾à ´ëÁ¶ ÀÓ»ó½ÃÇè |
2»ó |
PF-06290510 |
Çѱ¹·Î½´ |
20170913 |
ÀÌÀü¿¡ ¾à¹°À» Åõ¿©¹ÞÀº ÀûÀÌ ¾ø´Â ÁøÇ༺ BRAFV600 ¾ß»ýÇü Èæ»öÁ¾ ȯÀÚ¿¡¼ ÄÚºñ¸ÞƼ´Õ + ¾ÆÅ×Á¹¸®ÁÖ¸¿ VS Æèºê·Ñ¸®ÁÖ¸¿ÀÇ À¯È¿¼º°ú ¾ÈÀü¼ºÀ» ¿¬±¸ÇÏ´Â Á¦ 3»ó, °ø°³, ´Ù±â°ü, 2±º, ¹«ÀÛÀ§¹èÁ¤ ÀÓ»ó½ÃÇè |
1»ó |
Ƽ½ëÆ®¸¯(RO554-1267) |
Çѱ¹¾Æ½ºÆ®¶ó
Á¦³×Ä« |
20170913 |
ÀýÁ¦ºÒ°¡´ÉÇÑ °£¼¼Æ÷¾ÏÀÇ 1Â÷ ¼±Åà ġ·á·Î¼ Durvalumab°ú TremelimumabÀÇ ¹«ÀÛÀ§¹èÁ¤, °ø°³¶óº§, ´Ù±â°ü, Á¦III»ó ÀÓ»ó½ÃÇè (HIMALAYA) |
3»ó |
MEDI4736, Tremelimumab
|
|
|
|
|
|
|
|
|
FDA |
|
Drug Name and
FDA Appl. # |
Active Ingredients |
Submission
Classification |
Company |
Approval Date |
DAPTOMYCIN
NDA #208385 |
DAPTOMYCIN |
½ÅÁ¦Çü ¶Ç´Â ½ÅÁ¦Á¶¿ø |
SAGENT PHARMS |
09/12/2017 |
ALIQOPA
NDA #209936 |
COPANLISIB |
½Å¹°Áú |
BAYER HEALTHCARE PHARMS |
09/14/2017 |
MVASI
BLA #761028 |
BEVACIZUMAB-AWWB |
- |
AMGEN INC |
09/14/2017 |
ADZENYS ER
NDA #204325 |
AMPHETAMINE |
½Å¿ë·® |
NEOS THERAPS INC |
09/15/2017 |
SOLOSEC
NDA #209363 |
SECNIDAZOLE |
½Å¹°Áú |
SYMBIOMIX THERAPEUTICS LLC |
09/15/2017 |
|
|
|
EMA |
|
Name |
Active Substance |
Therapeutic area |
Date of authorisation/ refusal |
Mavenclad |
cladribine |
Multiple Sclerosis |
22/08/2017 |
|
|
|
|
|
|
|
|
Clinical.gov ¹Ì±¹ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03285607 |
MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer |
Breast Cancer
Cancer of Breast |
Biological: MCS110
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Paclitaxel
Procedure: Bone marrow aspirate
Procedure: Peripheral blood samples
Procedure: Tumor tissue |
Washington University School of Medicine|Novartis Pharmaceuticals |
Phase 1 |
NCT03283917 |
Study of Daratumumab, Ixazomib, and Dexamethasone in Previously Treated Amyloid Light Chain (AL) Amyloidosis |
Hematopoietic
/Lymphoid Cancer
Amyloid Light Chain (AL) Amyloidosis |
Drug: Daratumumab
Drug: Ixazomib
Drug: Dexamethasone |
M.D. Anderson Cancer Center
Janssen Scientific Affairs, LC
Takeda |
Phase 1 |
NCT03283631 |
Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM |
Recurrent Glioblastoma Multiforme
Recurrent Brain Tumor, Adult |
Biological: EGFRvIII-CARs |
Gary Archer Ph.D.
National Cancer Institute (NCI)
Duke Cancer Institute
Duke University |
Phase 1 |
NCT03283137 |
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL |
CLL
B-cell Non Hodgkin Lymphoma |
Drug: TGR-1202
Drug: Pembrolizumab |
University of Chicago |
Phase 1 |
NCT03283046 |
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma |
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Multiple Myeloma |
Drug: Nivolumab
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Ipilimumab |
M.D. Anderson Cancer Center|Bristol-Myers Squibb |
Phase 1 |
NCT03282344 |
A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma |
SARCOMA |
Drug: NKTR-214
Drug: Nivolumab |
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center |
Phase 2 |
NCT03283319 |
Panblok H7 Vaccine Adjuvanted With AS03 or MF59 Antigens |
Influenza, Human |
Biological: 3.75 ug Panblok H7
Biological: 7.5 ug Panblok H7
Biological: 15 ug Panblok H7
Biological: MF59
Biological: AS03 |
Biomedical Advanced Research and Development Authority
Rho, Inc. |
Phase 2 |
NCT03282240 |
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ¡Ã65 Years in the US |
Influenza |
Biological: QIV-HD
Biological: Licensed TIV-HD1
Biological: Investigational TIV-HD2 |
Sanofi Pasteur, a Sanofi Company
Sanofi |
Phase 3 |
|
|
Clinical.gov À¯·´ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
ºñ°í |
NCT03286751 |
A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants |
Diabetes Mellitus, Type 2 |
Drug: LY900014
Drug: Insulin Lispro |
Eli Lilly and Company |
Phase 1 |
µ¶ÀÏ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|